There are 4+ publications for this product available. The Mouse Monoclonal anti-p53 antibody is suitable to detect p53 in samples from Human and Primate. It has been validated for WB, IF, IHC (p), IP, IHC (fro) and EIA.
This Monoclonal antibody BP53-12 recognizes defined epitope (aa 16-25) on Human p53, a 50 kDa tumour suppressor found in increased amounts in a wide variety of transformed cells. It is frequently mutated or inactivated in many types of cancer.
ELISA. Western Blotting (Non-reducing conditions): Recommended Dilution: 1-2 μg/mL, overnight in 4 °CPositive Control: RAMOS Human lymphoma cell lineSample Preparation: Resuspend approx.50 mil. cells in 1 mLcold Lysis buffer(1 % laurylmaltoside in 20 mM Tris/Cl, 100 mM NaCl pH 8.2, 50 mM NaF including Proteaseinhibitor Cocktail). Incubate 60 min on ice. Centrifuge to remove cell debris. Mix lysatewith non-reducing SDS-PAGE sample buffer. SDS-PAGE: 12 % separating gel. Immunoprecipitation. Immunocytochemistry. Immunohistochemistry on Frozen and Paraffin-Embedded Sections. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
Phosphate buffered saline (PBS), pH ~7.4, 15 mM Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Bräuer, Kindler, Jäger, Sel, Nölle, Pleyer, Ochs, Paulsen: "Detection of surfactant proteins A and D in human tear fluid and the human lacrimal system." in: Investigative ophthalmology & visual science, Vol. 48, Issue 9, pp. 3945-53, (2007) (PubMed).
Li, Sainson, Shi, Leek, Harrington, Preusser, Biswas, Turley, Heikamp, Hainfellner, Harris: "Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo." in: Cancer research, Vol. 67, Issue 23, pp. 11244-53, (2007) (PubMed).
Dolezalová, Vojt?sek, Kovarík: "Epitope analysis of the human p53 tumour suppressor protein." in: Folia biologica, Vol. 43, Issue 1, pp. 49-51, (1997) (PubMed).
Bártková, Bártek, Lukás, Vojt?sek, Stasková, Rejthar, Kovarík, Midgley, Lane: "p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia." in: International journal of cancer. Journal international du cancer, Vol. 49, Issue 2, pp. 196-202, (1991) (PubMed).
Target
p53 (TP53)
(Tumor Protein P53 (TP53))
Alternative Name
p53 (TP53)
Background
The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.Synonyms: Cellular tumor antigen p53, NY-CO-13, Phosphoprotein p53, Tumor suppressor p53